Accenture Ventures backs Iridius to accelerate AI adoption in pharmaceutical sector.
By embedding regulatory standards into machine-readable logic, the collaboration seeks to move life sciences organizations from isolated AI pilots to enterprise-wide transformation.
Accenture has announced a strategic investment in Iridius, an enterprise AI infrastructure company specializing in "compliant-by-design" solutions. The investment, made through Accenture Ventures, is accompanied by a new strategic partnership designed to help life sciences and pharmaceutical organizations scale AI adoption while maintaining strict regulatory standards.
The collaboration intends to merge Accenture's deep industry knowledge and global delivery scale with Iridius' AI-powered regulatory capabilities. Together, the firms plan to build end-to-end compliance workflows across the life sciences value chain, covering areas from regulatory submissions and pharmacovigilance to clinical and manufacturing operations. The initiative is expected to reduce manual compliance workloads and accelerate clinical timelines.
Organizations in the life sciences sector are under increasing pressure to shorten the journey from research to patient treatment. However, success in this highly regulated environment requires harmonizing rapid AI adoption with rigorous frameworks for data integrity and patient safety. Iridius addresses these challenges by converting complex regulations and standard operating procedures into machine-readable logic, effectively embedding compliance directly into enterprise workflows.
"Our investment in Iridius is about giving life sciences organizations the ability to innovate without hesitation," said Ray Pressburger, global life sciences lead at Accenture. "By embedding compliance into the core of AI, we're helping accelerate clinical development, improve decision-making, and bring therapies to patients faster, all while meeting the rigorous expectations of regulators worldwide."
The Iridius platform architecture includes a "knowledge engine" that translates regulatory standards into structured logic and an "intelligent solution factory" to orchestrate compliant workflows. This system allows pharmaceutical companies to apply compliance as a foundational element of system design and provides the capability to monitor it continuously during execution, ensuring that evidence is generated as systems run.
Mike Kropp, co-founder and CEO of Iridius, noted that the partnership helps customers reimagine complex workflows by turning AI from a risk to be managed into a "trusted capability" that strengthens compliance and enables innovation. While the specific financial terms of the investment were not disclosed, the move underscores Accenture's commitment to ensuring that auditability is built into AI solutions from the outset.
SOURCE: Accenture
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.